 |
11/07/2006
PTC THERAPEUTICS INITIATES A PHASE 1 MULTIPLE-DOSE STUDY OF ITS NOVEL VEGF INHIBITOR, PTC299
|
9.8 KB |
| |
SOUTH PLAINFIELD, NJ – November 7, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the initiation of a Phase 1 multiple-dose study to evaluate escalating dose levels of PTC299 in healthy volunteer...
|
|
11/03/2006
PTC THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 RESULTS FOR PTC124 IN CYSTIC FIBROSIS
|
16.2 KB |
| |
SOUTH PLAINFIELD, NJ – November 3, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control processes, today announced the findings from two Phase 2 clinical trials of PTC124 in patients with cystic fibrosis (CF) due to a nonsense mu...
|
|
10/21/2006
PTC THERAPEUTICS ANNOUNCES ENCOURAGING PRELIMINARY PHASE 2 RESULTS OF PTC124 IN DUCHENNE MUSCULAR DYSTROPHY
|
11.5 KB |
| |
SOUTH PLAINFIELD, NJ – October 21, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control processes, today announced encouraging data from a Phase 2 clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to...
|
|
10/19/2006
FDA AWARDS PTC THERAPEUTICS ORPHAN PRODUCTS DEVELOPMENT GRANT FOR THE DEVELOPMENT OF PTC124 IN DUCHENNE MUSCULAR DYSTROPHY
|
10.1 KB |
| |
SOUTH PLAINFIELD, NJ – October 19, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control mechanisms, today announced it has been awarded a two-year grant from the Office of Orphan Products Development (OOPD) Grant Program of the U...
|
|
10/02/2006
PTC THERAPEUTICS ANNOUNCES $17.2 MILLION AWARD FROM THE UNITED STATES DEFENSE THREAT REDUCTION AGENCY
|
7.7 KB |
| |
SOUTH PLAINFIELD, NJ – October 2, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced that it has received a $17.2 million award from the United States Defense Threat...
|
|
09/26/2006
PTC THERAPEUTICS RECEIVES DEPARTMENT OF DEFENSE CLINICAL TRANSLATIONAL RESEARCH AWARD
|
9.4 KB |
| |
SOUTH PLAINFIELD, NJ – September 26, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced that it has received a three-year, $2.2 million grant from the Department of ...
|
|
06/12/2006
PTC THERAPEUTICS AND CV THERAPEUTICS ANNOUNCE COLLABORATION AND LICENSE ARRANGEMENT
|
10.1 KB |
| |
SOUTH PLAINFIELD, NJ, and PALO ALTO, CA, June 12, 2006 - PTC Therapeutics, Inc. and CV Therapeutics, Inc. (NASDAQ: CVTX) announced today that they have entered into an exclusive research collaboration and licensing arrangement for the development of orally bioavailable small molecules through the application of PTC's proprietary GEMS (Gene Expressi...
|
|
05/12/2006
PTC THERAPEUTICS INITIATES PHASE 1A CLINICAL TRIAL OF PTC299
|
7.3 KB |
| |
SOUTH PLAINFIELD, NJ - May 12, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced that it had commenced a Phase 1a clinical trial of the company's product candidate PTC29...
|
|
04/21/2006
PTC THERAPEUTICS ANNOUNCES PROMOTION OF CLÁUDIA HIRAWAT
|
42.5 KB |
| |
SOUTH PLAINFIELD, N.J., April 21, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced the promotion of Cláudia Hirawat to Senior Vice President of Corp...
|
|
04/04/2006
PTC THERAPEUTICS ANNOUNCES INTERIM PHASE 2 RESULTS OF PTC124 IN CYSTIC FIBROSIS
|
51.0 KB |
| |
SOUTH PLAINFIELD, N.J., April 4, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced interim results from Phase 2 clinical trials of PTC124 in patients...
|
|
03/31/2006
PTC THERAPEUTICS FILES FOR INITIAL PUBLIC OFFERING
|
45.6 KB |
| |
SOUTH PLAINFIELD, N.J., March 31, 2006 - PTC Therapeutics, Inc. today announced that the company has filed with the Securities and Exchange Commission a registration statement relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be sold by PTC Therapeutics, In...
|
|
03/30/2006
PTC THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FOR PTC124 IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
48.7 KB |
| |
SOUTH PLAINFIELD, N.J., March 30, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs that target post-transcriptional control processes, today announced that the company has been granted Fast Track designation from the United States Food and Drug Admi...
|
|
03/20/2006
SCHERING-PLOUGH AND PTC THERAPEUTICS ANNOUNCE COLLABORATION FOR DEVELOPMENT OF PTC'S PRECLINICAL HEPATITIS C COMPOUNDS
|
49.0 KB |
| |
KENILWORTH, N.J., and SOUTH PLAINFIELD, N.J., March 20, 2006 - Schering-Plough Corporation (NYSE: SGP) and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive collaboration and licensing agreement for the development of PTC’s preclinical compounds for the oral treatment of hepatitis C virus (HCV) infection and othe...
|
|
01/27/2006
PTC THERAPEUTICS INITIATES PHASE 2 STUDY OF PTC124 IN DUCHENNE MUSCULAR DYSTROPHY
|
45.5 KB |
| |
SOUTH PLAINFIELD, NJ - January 27, 2006 - PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced the initiation of a Phase 2 study of PTC124 in patients with Duchenne muscular dystrophy (DMD) due...
|
| Showing 1-14 of 14 |
Page: 1 |
|
|